Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
3.710
-0.150 (-3.89%)
At close: Jun 5, 2026, 4:00 PM EDT
3.800
+0.090 (2.43%)
After-hours: Jun 5, 2026, 7:57 PM EDT
Verastem Revenue
Verastem had revenue of $18.67M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $49.59M, up 395.85% year-over-year. In the year 2025, Verastem had annual revenue of $30.91M with 209.14% growth.
Revenue (ttm)
$49.59M
Revenue Growth
+395.85%
P/S Ratio
6.57
Revenue / Employee
$486,127
Employees
102
Market Cap
326.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 30.91M | 20.91M | 209.14% |
| Dec 31, 2024 | 10.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
| Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
| Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
| Dec 31, 2019 | 17.46M | -9.26M | -34.67% |
| Dec 31, 2018 | 26.72M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Enanta Pharmaceuticals | 69.21M |
| Invivyd | 55.87M |
| Abeona Therapeutics | 14.54M |
| Opus Genetics | 11.98M |
| Humacyte | 2.02M |
| Silence Therapeutics | 839.00K |
VSTM News
- 2 days ago - Verastem up 11% at $4.00 after announcing FDA Fast Track designation for VS-7375 - TheFly
- 2 days ago - Verastem announces FDA Fast Track designation for VS-7375 - TheFly
- 2 days ago - Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer - Business Wire
- 2 days ago - Verastem Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 9 days ago - Verastem Oncology to Present at Jefferies Healthcare Conference - Business Wire
- 10 days ago - Verastem appoints Michael Bailey to board of directors - TheFly
- 10 days ago - Verastem Oncology Appoints Michael P. Bailey to its Board of Directors - Business Wire
- 16 days ago - Verastem Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts